（Last updated : 2020-05-12 12:11:21）
Adoptive Immunotherapy of Cancer Using Autologous Lymphocytes, Cancer Growth and Progression
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.
Current Cancer Immunotherapy Using Activated Lymphocytes -Do Lymphocytes Actually Recognize Cancer Cells?
Imatinib Plasma Levels during Successful Long-Term Treatment of Metastatic Gastrointestinal Stromal Tumors
Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer
A case of stroke due to tumor emboli associated with metastatic cardiac liposarcoma
Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD2 antibody in adoptive immunotherapy of cancer.
Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432.
Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells.
Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Display 5 items
Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors
Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells
Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer.
Clinico-pathological features of hypermutant colorectal cancers analyzed over 1000 colorectal cancer
Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors
Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients
Heat shock protein 90 inhibitors suppress PDGFRA reactivation and other receptor tyrosine kinase activation important in drug resistant gastrointestinal stromal tumors.
HSP90 inhibitor inhibit the activation of multiple kinase pathways and migration of pancreatic
Imatinib plasma levels and clinical features of successful long-term treatment of metastatic gastrointestinal stromal tumors
Successful treatment of everolimus for a renal impairment patient with neuroendocrine tumor
The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma
Effect of HSP90 inhibitor on proliferation and migration in esophageal squamous cell carcinoma
Antitumor effect of HSP90 inhibitor against esophageal cancer
Clinicopathological study of gastrointestinal neuroendocrine tumor.
Possibility of combination therapy of molecular targeted drugs for gastrointestinal stromal tumor.
Antitumor effect of Hsp90 inhibitor in neuroendocrine tumor
Wnt signaling involved in gastrointestinal neuroendocrine tumors.
Cancer vaccine in combination with Anti-CD25 antibody for advanced esophageal squamous cell carcinoma. –a case of the prolonged stable disease
A case with postoperative bone metastasis of gastrointestinal stromal tumor (GIST) expressing exon 8 mutation of KIT
Cancer Vaccine in Combination with Anti-CD25 Antibody for Advanced Esophageal Squamous Cell Carcinomas –A Case of the Prolonged Stable Disease-
Targeting of CD4+CD25high cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer
CTL induction using cultured dendritic cells and tumor-RNA in gastric cancer
Display 5 items
© 2008 Kawasaki Medical School